A Study to Evaluate the Effects of 3 Months Dosing With GW856553, as Assessed FDG-PET/CT Imaging

NCT00633022 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

99

Enrollment

INDUSTRY

Sponsor class

Conditions

Atherosclerosis

Interventions

DRUG: LOSMAPIMOD 7.5 MG
DRUG: Placebo

Sponsor

GlaxoSmithKline